SCHEMBL4922844

SCHEMBL4922844

CCOC(=O)c1ccc(NC(=O)Nc2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.75
MEN1 O00255 3/20 0.75
KMT2A Q03164 3/20 0.75
TRPV1 Q8NER1 2/20 0.75
CASP3 P42574 1/20 0.75
SENP7 Q9BQF6 1/20 0.75
GAA P10253 2/20 0.66
NAMPT P43490 1/20 0.66
SMN1; SMN2 Q16637 6/20 0.66
RAB9A P51151 6/20 0.66
NPC1 O15118 4/20 0.66
CA12 O43570 1/20 0.64
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
CA9 Q16790 1/20 0.64
ALDH1A1 P00352 2/20 0.64
TSHR P16473 1/20 0.63
TP53 P04637 1/20 0.61
POLB P06746 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1019967 0.90 SMN1; SMN2 (0.78) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4113307 0.89 MAPT (0.77) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4915127 0.87 MAPT (0.75) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4111110 0.87 MAPT (0.75) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4112088 0.87 KMT2A (0.75) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL9422337 0.86 SMN1; SMN2 (0.73) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4913447 0.86 SMN1; SMN2 (0.74) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL27063 0.86 CA1 (0.70) MAPTMEN1KMT2AGAASMN1; SMN2
Terephthalic Acid SCHEMBL28214245 0.86 CA1 (0.70) MAPTMEN1KMT2AGAASMN1; SMN2
Terephthalic Acid SCHEMBL28214246 0.86 CA1 (0.70) MAPTMEN1KMT2AGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MAPT 4151/4885MEN1 4843/4885KMT2A 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.